Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Instead, the lack of EGF receptor is frequently found in SCLC cell lines and is distinct from the other types of lung cancer.
|
3032412 |
1987 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that NSCLC in contrast to SCLC expresses high levels of EGF receptors which may be used to facilitate the differential diagnosis in some cases of lung cancer.
|
2830015 |
1988 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, the EGF/DNA complex can deliver therapeutic genes to lung cancer cells by targeting to specific receptors.
|
8785711 |
1996 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor (EGF)/DNA complexes targeted to cancer cells overexpressing the EGF receptor resulted in efficient transduction of several lung cancer cell lines in vitro.
|
9727626 |
1998 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that EGF doubles the proliferation (growth in soft agar as well as tumorigenicity in athymic mice) of A549 lung carcinoma cells and that the JNK2 isoform but not JNK1 is utilized for mediating the effects of EGF.
|
10022881 |
1999 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
|
12867060 |
2003 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we present evidence that TR3 was also induced by epidermal growth factor (EGF) and serum and was required for their mitogenic effect in lung cancer cells.
|
14612408 |
2003 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors have previously shown that DAB(389)EGF is selectively toxic to EGFR-overexpressing cells, including human brain tumour and lung carcinoma cell lines.
|
14519080 |
2003 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.
|
15539955 |
2004 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In lung cancer cell lines, CpG island methylation was frequently detected for TIMP4 (64%), SOX18 (73%), EGF-like domain 7 (56%), CD105 (71%), SEMA2 (55%), RASSF1A (71%), p16 (56%) SLIT2 (100%) and TIMP3 (29%).
|
15911247 |
2005 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population.
|
15663953 |
2005 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the mechanisms by which airway inflammatory agents mediate the expression of sialyl-Lewis x epitopes and MUC5AC mucin, we examined the effects of tumor necrosis factor (TNF)-alpha and epidermal growth factor (EGF) in the human lung carcinoma cell line, NCI-H292.
|
15864435 |
2005 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
|
16766261 |
2006 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that Mig-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines.
|
16819504 |
2007 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, expression of BCR, which is required for EGFR protein degradation, was induced by EGF stimulation, suggesting a negative feedback loop in lung cancer.
|
17459062 |
2007 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the EGF+61 A>G polymorphism may not significantly affect the susceptibility to lung cancer in the Korean population.
|
17986122 |
2007 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment.
|
18687633 |
2008 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since a high percentage of lung adenocarcinoma in Asian female nonsmokers contains activating hotspot mutations in epidermal growth factor receptors (EGFR), we hypothesized that NAT2 polymorphisms might represent a risk factor in lung cancer with EGFR mutations.
|
18706736 |
2009 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In lung cancer the role of the EGF-EGFR transduction pathway has been documented, whereas androgen activity has received less attention.
|
18692155 |
2009 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the time-dependent PIAS3 shuffling and binding to STAT3 in an EGF-dependent model in lung cancer by using confocal microscopy, immunoprecipitation, luciferase reporter assay, and protein analysis of segregated cellular components.
|
19903771 |
2009 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the ability of NMB to cause transactivation of the epidermal growth factor (EGF) receptor in lung cancer cells.
|
20388507 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential ligand-binding sites within the epidermal growth factor (EGF)-like repeats of Notch1 have been identified, but the ligand-binding domains in Notch3, which is implicated in lung cancer, are not known.
|
20068176 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.
|
21777670 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated the concentration-dependent negative regulatory effect of PIAS3 on STAT3 signaling and its capacity to decrease lung cancer proliferation and synergize with epidermal growth factor inhibition.
|
21497567 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
|
21712056 |
2011 |